Research ArticleArticle
Open Access
Prologue: Evidence Informing the GRAPPA 2021 Treatment Recommendations, by Domain
Enrique R. Soriano, Arthur Kavanaugh and Laura C. Coates
The Journal of Rheumatology October 2022, jrheum.220486; DOI: https://doi.org/10.3899/jrheum.220486
Enrique R. Soriano
This work was supported by GRAPPA. ERS participated in advisory boards, gave conferences, or received grants from AbbVie, Amgen, BMS, Eli Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has consulted for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and UCB. LCC has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis, and Pfizer; worked as a paid consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer, and UCB. E.R. Soriano, MD, University Institute, and Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, California, USA; L.C. Coates, PhD, MBChB, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Address correspondence to Dr. E.R. Soriano, Unidad de Reumatologia, Servicio de Clinica Medica, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Péron 4190, C1199 CABA, Argentina. Email: enrique.soriano@hospitalitaliano.org.ar. Accepted for publication May 3, 2022.
Arthur Kavanaugh
This work was supported by GRAPPA. ERS participated in advisory boards, gave conferences, or received grants from AbbVie, Amgen, BMS, Eli Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has consulted for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and UCB. LCC has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis, and Pfizer; worked as a paid consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer, and UCB. E.R. Soriano, MD, University Institute, and Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, California, USA; L.C. Coates, PhD, MBChB, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Address correspondence to Dr. E.R. Soriano, Unidad de Reumatologia, Servicio de Clinica Medica, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Péron 4190, C1199 CABA, Argentina. Email: enrique.soriano@hospitalitaliano.org.ar. Accepted for publication May 3, 2022.
Laura C. Coates
This work was supported by GRAPPA. ERS participated in advisory boards, gave conferences, or received grants from AbbVie, Amgen, BMS, Eli Lilly, GSK, Janssen, Novartis, Pfizer, Sandoz, Roche, and UCB. AK has consulted for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and UCB. LCC has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis, and Pfizer; worked as a paid consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer, and UCB. E.R. Soriano, MD, University Institute, and Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, California, USA; L.C. Coates, PhD, MBChB, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Address correspondence to Dr. E.R. Soriano, Unidad de Reumatologia, Servicio de Clinica Medica, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Péron 4190, C1199 CABA, Argentina. Email: enrique.soriano@hospitalitaliano.org.ar. Accepted for publication May 3, 2022.
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory disease that is remarkably diverse in its presentation and course. Important domains of involvement include peripheral arthritis, skin and nail psoriasis, enthesitis, dactylitis, and axial arthritis, along with associated conditions such as inflammatory bowel disease (IBD) and anterior uveitis.1,2
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Prologue: Evidence Informing the GRAPPA 2021 Treatment Recommendations, by Domain
Enrique R. Soriano, Arthur Kavanaugh, Laura C. Coates
The Journal of Rheumatology Oct 2022, jrheum.220486; DOI: 10.3899/jrheum.220486